Last reviewed · How we verify
ORS only
At a glance
| Generic name | ORS only |
|---|---|
| Sponsor | Society for Applied Studies |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Upper respiratory tract infection
- Diarrhoea
- Laryngitis
- Bronchiolitis
- Dermatitis
Key clinical trials
- Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea (PHASE4)
- Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat. (PHASE4)
- Effectiveness Study During the First 1,000 Days in Kenya (NA)
- Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects (PHASE1)
- Racecadotril Versus Standard Treatment in Decreasing the Duration of Acute Diarrhoea in Children (PHASE1, PHASE2)
- Clinical Study to Compare the Effect of an Oral Rehydration Solution on the Rate of Absorption of Functional Ingredients (NA)
- Water, Sanitation, and Hygiene Mobile Health Messages as an Innovative Tool to Facilitate Behavior Change (NA)
- Study to Evaluate the Efficacy and Safety of Racecadotril in Children Aged 3 to 60 Months Suffering From Acute Diarrhea (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ORS only CI brief — competitive landscape report
- ORS only updates RSS · CI watch RSS
- Society for Applied Studies portfolio CI